期刊文献+

血管紧张素系统阻断剂对慢性肾脏疾病患者血清AngⅡ、TGF-β_1水平的影响 被引量:1

Influnce of angiotensin system blockers on the levels of serum angiotensin Ⅱ and TGF-β_1 in chronic glomerular disease patients
下载PDF
导出
摘要 目的观察苯那普利(ACEI)、缬沙坦(ARB)及两药联合应用对慢性肾小球疾病患者血清血管紧张素Ⅱ(AngⅡ)、转化生长因子-β1(TGF-β1)水平的影响。方法89例伴有蛋白尿的慢性肾小球疾病患者随机分为3组,苯那普利组(ACEI)、缬沙坦组(ARB)和联合组(苯那普利+缬沙坦),疗程8~12周。分别检测各组的AngⅡ、TGF-β1、肾功能、24h尿蛋白定量及血压。结果苯那普利组及联合治疗组血清AngⅡ水平均较治疗前显著降低(P<0.05),缬沙坦组血清AngⅡ水平较治疗前上升(P<0.05),各组血清TGF-β1水平均较治疗前下降,差异有统计学意义(P<0.05),其中治疗后各组间单因素方差分析表明,联合治疗组血清TGF-β1水平与单独用药组相比差异有统计学意义(P<0.05)。治疗后各组蛋白尿均降低(P<0.05),苯那普利组及缬沙坦组之间差异无统计学意义(P>0.05),联合治疗组降低蛋白尿疗效优于苯那普利组及缬沙坦组(P<0.05)。结论苯那普利和缬沙坦联合治疗慢性肾小球疾病,可下调AngⅡ、TGF-β1的表达,进一步降低蛋白尿。 Objective To investigate the effect of angiotensin sestem blockers( ACEI, ARB,or combination of them) on the levels of serum Ang Ⅱ、TGF - β1 in patients with chronic glomerular disease. Methods 89 cases of chronic glomerular disease were randomly divided into 3 groups. Group A : benazepril alone ( 30 cases) ; Group B : valsartan alone ( 30 cases) ; and Group C : combination of benazepril and valsartan ( 29 cases). The serum Ang Ⅱ、TGF - β1, renal function, quantity of 24 hour urinary protein, systolic pressure and diastolic pressure were measured before and after 8 - 12 weeks therapy. Results The level of serum Ang Ⅱ was effectively decreased in Group A and Group C ( P 〈 0.05 ), in contrast to GroupC, the level of serum Ang Ⅱ was increased (P 〈 0.05). Not only did combination of ACEI and ARB therapy reduce serum TGF - β1 more significantly than each of monotherapy did ( P 〈 0.05). but also decreased proteinuria more effectively than that of benazepril alone or valsartan alone ( P 〈 0.05 ) Conclusion The combination of benazepril and valsartan may reduce the level of serum Ang Ⅱ、TGF - β1, and decrease urine protein excretion furthermore in patients with chronic glomerular disease
出处 《安徽医学》 2007年第4期285-288,共4页 Anhui Medical Journal
基金 安徽省学术和技术带头人后备人选科学研究基金资助项目(2002HBL25)
关键词 苯那普利 缬沙坦 联合用药 血管紧张素Ⅱ 转化生长因子Β1 Benazepril Valsartan Angiotensin Ⅱ Transforming growth factor-β1
  • 相关文献

参考文献14

  • 1Chobanian AV,Bakris GL,Black HR,et al.The Seventh Roport of the Joint National Committee on Prevention,Detection,Evaluation,and Treatment of High Blood Pressure:the JNC 7 report.JAMA,2003 ;289:2560 - 2572
  • 2European Society of Hypertention-European Society of Cardiology Guidelines Committee.2003,European Society of Hypertention-European Society of Cardiology Guidelines for the management of arterial hypertension.J Hypertens,2003; 21:1011 -1053
  • 3Kobori H,Harrison-Bemard LM,Navar LG.Enhancement of angiotensinogen expression in angiotensin Ⅱ -dependent hypertension.Hypertension,2001 ;37:1239 - 1335
  • 4Liu BC,Sun J,Chen Q,et al.Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin Ⅱ.Nephrol,2003 ;23(6):429 -437
  • 5Del Prete D,Gambaro G,Lupo A,et al.Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis.Kidney Int,2003 ;64(1):149 -159
  • 6Mezzano SA,Aros CA,Droguett A,et al.Renal angiotensin Ⅱ up-regulation and myofibroblast activation in human membranous nephropathy.Kidney Int Suppl,2003; 64 (Suppl 86):S39- S45
  • 7Li PK,Leung CB,Chow KM,et al.Hong Kong study using valsartan in IgA nephropathy (HKVIN):a double-blind,randomized,placebo-controlled study.Am J Kidney Dis,2006; 47(5):751 -760
  • 8Praga M,Andrade CF,Lu(n)o J,et al.Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases:a double-blind,randomized clinical trial.Nephrol Dial Transplant,2003; 18 (9):1806 - 1813
  • 9Hunley TE,Tamura M,Stoneking BJ,et al.The angiotensin type Ⅱ receptor tonically inhibits angiotensin-converting enzyme in AT2 nullmutant mice.Kidney Int,2000 ;57 (2):570 - 577
  • 10Siragy HM,de Gasparo M,E1 -Kersh M,et al.Angiotensin -converting enzyme inhibition potentiates angiotensin Ⅱ type 1 receptor effects on renal bradykinin and cGMP.Hypertension,2001 ;38:183 - 186

同被引文献11

  • 1周秋根,郑法雷,文煜冰,谭小月,段林,李艳.己酮可可碱对肾小管上皮细胞转分化抑制作用的实验研究[J].中国中西医结合肾病杂志,2005,6(1):4-9. 被引量:3
  • 2傅淑霞,王希倩,郝玉杰,杨林.己酮可可碱对单侧输尿管梗阻大鼠肾间质纤维化的保护作用及其机制[J].中国医师杂志,2006,8(5):580-583. 被引量:5
  • 3Lin SL, Chen YM, Chien CT, et al. Pentoxifylline attenuated the renal disease progression in rats with renmant kidney[J]. JASN, 2002, 13(12) :2916- 2929.
  • 4Benigni A, Remuzzi G. How renal cytokines and growth factor contribute to renal disease progression [ J]. Am J Kindney Dis, 2001,37(Suppl 2) :S21 - 24.
  • 5Abbate M, Zoja C, Morigi M, et al. Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclemsis [ J]. Am J Pathol, 2002,161 (6) :2179 - 2193.
  • 6Chen YM, Lin SL, Chiang WC, et al. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases [ J ]. Kidney Int, 2006, 69 (8) : 1410 - 1415.
  • 7Panzer U, Thaiss F, Zahner G, et al. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis [J]. Kidney Int, 2001,59(5) : 1762- 1769.
  • 8Taal MW,Zandi-Nejad K, Weening B, et al. Pminflammatory gene expression and macrophage recruitment in the rat remnant kidney [ J ]. Kidney Int, 2000, 58 (4) : 1664 - 1676.
  • 9Chen YM, Nq YY, Lin SL, et al. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescenlic glomerulonephritis in rats [ J ]. Nephrol Dial Transplant, 2004,19(5) : 1106 - 1115.
  • 10Ng YY, Chen YM, Tsai TJ, et al. Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats[J]. Am J Nephrol, 2008,29( 1 ) : 43 - 53.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部